Loading clinical trials...
Loading clinical trials...
A Phase 1b Trial of Hu5F9-G4 in Combination With Avelumab in Solid Tumor Patients and Checkpoint-Inhibitor-Naive Ovarian Cancer Patients Who Progress Within 6 Months of Prior Platinum Chemotherapy
Conditions
Interventions
Magrolimab
Avelumab
Locations
6
United States
University of Chicago
Chicago, Illinois, United States
START Midwest
Grand Rapids, Michigan, United States
Oklahoma University Health Sciences Center
Oklahoma City, Oklahoma, United States
University of Texas Southwestern Medical Center
Dallas, Texas, United States
South Texas Accelerated Research Therapeutics, LLC
San Antonio, Texas, United States
University of Washington
Seattle, Washington, United States
Start Date
May 23, 2018
Primary Completion Date
December 3, 2020
Completion Date
December 3, 2020
Last Updated
April 1, 2024
NCT03050268
NCT06257264
NCT06964009
NCT00539162
NCT06710548
NCT06915025
Lead Sponsor
Gilead Sciences
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions